TNFRSF18 and melanoma: Regarding their therapeutic effect, G2 PD-L1-targeting 4-1BB-inserted CAR-T cells had superior anti-tumor activity over CD28- and GITR-incorporated CAR-T cells in mouse models of melanoma and lymphoma [18].